Anika Reports Third Quarter Fiscal 2022 Financial Results

Rhea-AI Summary

Anika Therapeutics reported a 2% revenue growth for Q3 2022, totaling $40.3 million. Key product segments included OA Pain Management at $25.7 million (down 2%) and Non-Orthopedic revenue at $2.8 million (up 27%). The company experienced a net loss of $4.2 million or $(0.29) per share, compared to net income of $0.6 million in Q3 2021. Notably, the Phase III trial for Cingal achieved primary endpoints, demonstrating superiority over steroid treatment. The Hyalofast trial is nearing full enrollment, and the company remains on track to meet FY2022 guidance.

Positive

• Successful Phase III trial for Cingal demonstrates superiority over steroid, advancing towards FDA approval.
• 96% enrollment in Hyalofast pivotal clinical trial, expected to file for PMA in 2025.
• Continued growth in Non-Orthopedic revenue, increasing by 27%.

Negative

• Net loss of $4.2 million, compared to a net income of $0.6 million in Q3 2021.
• OA Pain Management revenue declined by 2%.

Third Quarter Revenue Growth of 2%

Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone

Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-Stage Cartilage Repair Product, Reaches 96% Enrollment

Positive Feedback from Limited Market Release of New X-Twist™ Fixation System for Soft Tissue Repair; On Track for Full Market Release in Early 2023

On Track to Achieve Stated FY2022 Guidance

BEDFORD, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its third quarter ended September 30, 2022.

Third Quarter 2022 Financial Summary

• Revenue in the third quarter of 2022 was $40.3 million, up 2% compared with $39.5 million in the third quarter of 2021.
  • OA Pain Management¹ revenue of $25.7 million, down 2%
  • Joint Preservation and Restoration revenue of $11.8 million, up 6%
  • Non-Orthopedic¹ revenue of $2.8 million, up 27%
• Gross margin was 57%, including $1.6 million of non-cash acquisition-related expenses and $2.6 million product rationalization charges; Adjusted gross margin² was 67%.
• Net loss was ($4.2) million, or ($0.29) per share, compared to net income of $0.6 million, or $0.04 per diluted share, in the prior year. Adjusted net loss² was ($0.7) million, or ($0.05) per share, compared to adjusted net income² of $0.8 million, or $0.05 per diluted share, in the prior year.
• Adjusted EBITDA² was $4.1 million, compared to adjusted EBITDA² of $5.7 million in the prior year.
• Operating cash flow was $2.7 million; quarter ending cash was $87.8 million after a $4.3 million payment for acquisition-related contingent consideration, with no outstanding debt.

¹ OA Pain Management was previously referred to as Joint Pain Management; Non-Orthopedic was previously referred to as Other.
² See description of non-GAAP financial information contained in this release.

“We’re pleased with our third quarter accomplishments including our limited launch of the X-Twist Fixation System, successful results from our Cingal Phase III clinical trial, significant progress enrolling the Hyalofast pivotal clinical trial, and solid financial performance,” Cheryl R. Blanchard, Ph.D., Anika’s President and CEO, commented. “Our limited launch of the X-Twist platform has been very positive to date, and we remain on track for the full launch in early 2023. We also recently announced the successful results from our third Phase III clinical trial for Cingal which demonstrated superiority over steroid alone and we look forward to meeting with the FDA to determine next steps for U.S. regulatory approval. Despite the global macroeconomic environment, including staffing and supply chain challenges, we are confident that our strong cash position and no debt, robust foundation of clinical data, comprehensive product and technology portfolio, and exciting new product pipeline all position us for accelerated growth as we drive value for Anika shareholders.”

Recent 2022 Business Highlights

• Continued Leadership in OA Pain Market
  • Maintained #1 U.S. market share position in OA Pain Management with Monovisc® and Orthovisc®. In August 2022, DePuy Mitek extended our license and supply agreement for Orthovisc for another 5-year term through December 2028.
  • International viscosupplement sales continued accelerated growth, including Cingal which is currently sold in over 35 countries.
• Building a Best-in-Class Portfolio of Joint Preservation and Restoration Solutions
  • Continued accelerated growth of Tactoset®, Anika’s regenerative solution for insufficiency fractures and soft tissue hardware augmentation, with multiple planned 510(k) filings targeting further expansion.
  • First surgeries were performed with strong positive surgeon feedback during the limited market release of the X-Twist Fixation System, a new addition to the Anika sports medicine portfolio that addresses the needs of surgeons performing high volume soft tissue repair procedures, such as rotator cuff; on track for a full market release in early 2023.
  • Advanced development of multiple new products across the largest and fastest growing parts of the joint preservation market, including new innovative shoulder implants and a regenerative rotator cuff repair system.
• Ramping Up Medical Education Activities
  • Held multiple medical education events, training more than 400 U.S. surgeons in-person to date this year in addition to other training activities at industry meetings.
• Advancing Cingal Towards U.S. Regulatory Approval
  • Announced that Cingal, Anika’s next generation product for osteoarthritis patients, successfully achieved its primary endpoint in a third Phase III clinical trial, Cingal 19-01, which demonstrated the superiority of Cingal over steroid alone, for OA pain relief at 26 weeks.
  • Together with previous studies, Cingal has now demonstrated superiority over each of its active ingredients and placebo, and consistently demonstrating strong and durable pain relief in OA patients.
  • Company to engage with the FDA in the coming months regarding next steps for U.S. regulatory approval and explore the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets. These efforts will inform next steps, including if and how to proceed with another clinical trial in the United States.
• Continuing Clinical Trial Enrollment for Hyalofast Pivotal Phase III Clinical Trial
  • Delivered significant progress towards clinical study enrollment for the Company’s differentiated HA-based single-stage cartilage repair product, Hyalofast, which is now 96% enrolled with 193 patients randomized between Hyalofast implantation and the microfracture surgical technique.
  • Company expects the trial to be fully enrolled in early 2023 and remains on track to file a Pre-Market Approval with the FDA in 2025.

Fiscal 2022 Outlook
The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid single-digit growth compared with 2021. Revenue ranges by product family are:

• OA Pain Management up mid to upper single-digit percent (previously low single-digit percent)
• Joint Preservation and Restoration up low to mid single-digit percent (previously mid single to low double-digit percent)
• Non-Orthopedic down approximately 20% due largely to legacy product rationalization  
  

There remains volatility and uncertainty in the global macroeconomic environment and the Company’s outlook for fiscal 2022 is subject to the changing dynamics associated with staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the COVID pandemic.

Conference Call Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Tuesday, November 8, 2022, at 5:00 pm ET. The conference call can be accessed by dialing 1-888-256-1007 (toll-free domestic) or 1-856-344-9221 (international) and providing the conference ID number 2205523. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, sports medicine soft tissue repair and bone preserving joint technologies, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, MONOVISC, ORTHOVISC, TACTOSET, X-TWIST and the Anika logo are registered trademarks of Anika Therapeutics, Inc. or its subsidiaries.

Non-GAAP Financial Information
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted Gross Margin
Adjusted gross margin is defined by the Company as adjusted gross profit divided by total revenue. The Company defines adjusted gross profit as GAAP gross profit excluding amortization of certain acquired assets, the impact of inventory fair-value step up associated with our recent acquisitions and non-cash product rationalization charges.

Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, acquisition related expenses, non-cash charges related to goodwill impairment and changes in the fair value of contingent consideration associated with the Company’s recent acquisitions as a result of the COVID pandemic, and non-cash product rationalization charges.

Adjusted Net Income (Loss) and Adjusted EPS
Adjusted net income (loss) is defined by the Company as GAAP net income excluding acquisition related expenses, inclusive of the impact of purchase accounting, on a tax effected basis, and the non-cash product rationalization charges. In the context of adjusted net income (loss), the impact of purchase accounting includes amortization of inventory step up and intangible assets recorded as part of purchase accounting for acquisition transactions. The amortized assets contribute to revenue generation, and the amortization of such assets will recur in future periods until such assets are fully amortized. These assets include the estimated fair value of certain identified assets acquired in acquisitions in 2020 and beyond, including in-process research and development, developed technology, customer relationships and acquired tradenames. As a result of COVID, the Company is also specifically excluding the impacts of goodwill impairment charges and changes in the fair value of contingent consideration associated with the acquisition transactions, each on a tax effected basis. Adjusted diluted EPS is defined by the Company as GAAP diluted EPS excluding acquisition related expenses and the impact of purchase accounting, each on a tax-adjusted per share basis, and non-cash product rationalization charges. Again, the Company is also specifically excluding the impacts of goodwill impairment charges and changes in the fair value of contingent consideration associated with recent acquisition transactions, each on a tax effected basis if applicable.

A reconciliation of adjusted gross profit to gross profit (and the associated adjusted gross margin calculation), adjusted EBITDA to net income (loss), adjusted net income (loss) to net income (loss) and adjusted diluted EPS to diluted EPS, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including the subheadings at the top of the press release with respect to the planned launch of the X-Twist and FY2022 guidance, the second, third and final sentences of Dr. Blanchard’s quote, the bullets with respect to the planned launch of the X-Twist, the anticipated meeting with the FDA and potential partnerships regarding Cingal, and the anticipated Hyalofast enrollment and filing of a Pre-Market Approval, all in the section titled Recent 2022 Business Highlights, and the statements made in the section titled Fiscal 2022 Outlook. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
			2022				2021				2022				2021
Revenue		$	40,264			$	39,536			$	116,614			$	111,973
Cost of Revenue			17,485				16,513				47,169				47,164
Gross Profit			22,779				23,023				69,445				64,809
Operating expenses:
Research and development			7,301				7,673				20,433				21,327
Selling, general and administrative			21,276				17,500				61,745				53,664
Change in fair value of contingent consideration			-				(3,450	)			-				(21,920	)
Total operating expenses			28,577				21,723				82,178				53,071
(Loss) income from operations			(5,798	)			1,300				(12,733	)			11,738
Interest and other income (expense), net			436				(48	)			378				(141	)
(Loss) income before income taxes			(5,362	)			1,252				(12,355	)			11,597
(Benefit from) provision for income taxes			(1,187	)			694				(2,404	)			1,670
Net (loss) income		$	(4,175	)		$	558			$	(9,951	)		$	9,927
Net (loss) income per share:
Basic		$	(0.29	)		$	0.04			$	(0.68	)		$	0.69
Diluted		$	(0.29	)		$	0.04			$	(0.68	)		$	0.68
Weighted average common shares outstanding:
Basic			14,603				14,429				14,542				14,389
Diluted			14,603				14,647				14,542				14,588

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
	September 30,				December 31,
ASSETS		2022				2021
Current assets:
Cash, cash equivalents and investments	$	87,777			$	94,386
Accounts receivable, net		34,168				29,843
Inventories, net		37,237				36,010
Prepaid expenses and other current assets		8,579				8,289
Total current assets		167,761				168,528
Property and equipment, net		47,390				47,602
Right-of-use assets		30,987				20,957
Other long-term assets		18,342				20,285
Intangible assets, net		76,545				82,382
Goodwill		6,721				7,781
Total assets	$	347,746			$	347,535
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	8,353			$	7,633
Accrued expenses and other current liabilities		17,999				17,847
Contingent consideration		-				4,315
Total current liabilities		26,352				29,795
Other long-term liabilities		474				1,258
Deferred tax liability		6,800				10,157
Lease liabilities		29,183				19,240
Stockholders' equity:
Common stock, $0.01 par value		146				144
Additional paid-in-capital		76,661				67,081
Accumulated other comprehensive loss		(7,497	)			(5,718	)
Retained earnings		215,627				225,578
Total stockholders' equity		284,937				287,085
Total liabilities and stockholders' equity	$	347,746			$	347,535

Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit
(in thousands)
(unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
			2022				2021				2022				2021
Gross Profit		$	22,779			$	23,023			$	69,445			$	64,809
Product rationalization related charges			2,636								2,636				2,063
Acquisition related intangible asset amortization			1,562				1,562				4,686				4,686
Acquisition related inventory step up			-				1,458				-				6,244
Adjusted Gross Profit		$	26,977			$	26,043			$	76,767			$	77,802
Unadjusted Gross Margin			57	%			58	%			60	%			58	%
Adjusted Gross Margin			67	%			66	%			66	%			69	%
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income to Adjusted EBITDA
(in thousands)
(unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
			2022				2021				2022				2021
Net (loss) income		$	(4,175	)		$	558			$	(9,951	)		$	9,927
Interest and other expense, net			(436	)			48				(378	)			141
Benefit from income taxes			(1,187	)			694				(2,404	)			1,670
Depreciation and amortization			1,549				1,789				4,980				5,226
Stock-based compensation			3,876				2,863				10,502				7,919
Product rationalization			2,636				-				2,636				2,063
Acquisition related intangible asset amortization			1,787				1,787				5,361				5,361
Acquisition related inventory step up			-				1,458				-				6,244
Change in fair value of contingent consideration			-				(3,450	)			-				(21,920	)
Adjusted EBITDA		$	4,050			$	5,747			$	10,746			$	16,631
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income to Adjusted Net Income
(in thousands)
(unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
			2022				2021				2022				2021
Net (loss) income		$	(4,175	)		$	558			$	(9,951	)		$	9,927
Product rationalization, tax effected			2,056				-				1,947				1,590
Acquisition related intangible asset amortization, tax effected			1,394				1,146				3,960				3,898
Acquisition related inventory step up, tax effected			-				935				-				4,626
Change in fair value of contingent consideration, tax effected			-				(1,865	)			-				(17,152	)
Adjusted net (loss) income		$	(725	)		$	774			$	(4,044	)		$	2,889
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share
(per share data)
(unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
			2022				2021				2022				2021
Diluted (loss) earnings per share (EPS)		$	(0.29	)		$	0.04			$	(0.68	)		$	0.68
Product rationalization, tax effected			0.14				-				0.13				0.11
Acquisition related intangible asset amortization, tax effected			0.10				0.08				0.27				0.27
Acquisition related inventory step up, tax effected			-				0.06				-				0.32
Change in fair value of contingent consideration, tax effected			-				(0.13	)			-				(1.18	)
Adjusted diluted (loss) earnings per share (EPS)		$	(0.05	)		$	0.05			$	(0.28	)		$	0.20

Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
(in thousands, except percentages)
(unaudited)
	For the Three Months Ended September 30,															For the Nine Months Ended September 30,
		2022				2021			$ change				% change				2022				2021			$ change				% change
OA Pain Management	$	25,665			$	26,153			$	(488	)		-2	%		$	74,139			$	69,790			$	4,349			6	%
Joint Preservation and Restoration		11,821				11,193				628			6	%			36,055				35,296				759			2	%
Non-Orthopedic		2,778				2,190				588			27	%			6,420				6,887				(467	)		-7	%
Revenue	$	40,264			$	39,536			$	728			2	%		$	116,614			$	111,973			$	4,641			4	%

 

FAQ

What were Anika Therapeutics' Q3 2022 revenue figures?

Anika Therapeutics reported Q3 2022 revenues of $40.3 million, a 2% increase from $39.5 million in Q3 2021.

How did the Cingal clinical trial perform?

The Phase III clinical trial for Cingal achieved its primary endpoint, demonstrating superiority over steroid treatment for OA pain relief.

What is the expected outcome for the Hyalofast clinical trial?

The Hyalofast pivotal clinical trial is 96% enrolled and is expected to file for Pre-Market Approval with the FDA in 2025.

What is the projected revenue guidance for Anika Therapeutics in FY2022?

Anika expects FY2022 revenue growth toward the upper end of low to mid-single-digit growth compared to 2021.

What factors contributed to the net loss reported by Anika in Q3 2022?

Anika reported a net loss of $4.2 million due to various factors, including increased expenses and a decline in OA Pain Management revenue.